Please try another search
Dominari Holdings Inc., formerly AIkido Pharma Inc., is a biotechnology company. The Company has a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from universities and researchers. The Company advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, is a chemotherapy treatment for advanced pancreatic cancer.
Name | Age | Since | Title |
---|---|---|---|
Anthony C. Hayes | 55 | 2013 | CEO & Chairman |
Scott T. Tagawa | - | 2021 | Member of Scientific Advisory Board |
Soo Yu | 52 | 2022 | Independent Director |
Kyle B. Haug | 40 | 2023 | Director |
Timothy Steven Ledwick | 66 | 2015 | Independent Director |
Robert Dudley | 68 | 2020 | Independent Director |
Kyle Michael Wool | 46 | 2021 | President & Director |
Gregory James Blattner | 45 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review